• Policy
• Daewoong also enter the Vemlidy late-stage drug market
• by Lee, Tak-Sun Feb 23, 2023 05:46am

• Policy
• 9 bepotastine besilate antihistamines listed for reimb
• by Lee, Tak-Sun Feb 23, 2023 05:46am

• Company
• Tabreca can now be prescribed at general hospitals in Korea
• by Eo, Yun-Ho Feb 23, 2023 05:46am

• Company
• Neulasta's sales surpassed those of Neulapeg
• by Kim, Jin-Gu Feb 23, 2023 05:46am

• Policy
• SGLT-2 DM Combi Benefit Expansion Expected to be applied
• by Lee, Tak-Sun Feb 23, 2023 05:45am

• Company
• Celltrion Eyelea expands U.S. patent
• by Feb 22, 2023 05:55am

• Policy
• The ruling party promotes the establishment of a serious dz
• by Lee, Jeong-Hwan Feb 22, 2023 05:54am

• Policy
• Lucentis biosimilar Ameliebou prices cut 24.5% voluntarily
• by Kim, Jung-Ju Feb 22, 2023 05:54am

• Policy
• Chong Kun Dang's Tamivir is listed as the lowest price
• by Lee, Tak-Sun Feb 22, 2023 05:54am

• Policy
• Revlimid generics also allowed reimb for MDS
• by Lee, Tak-Sun Feb 22, 2023 05:54am